TERT promoter mutations rather than methylation are the main mechanism for TERT upregulation in adult gliomas

Acta Neuropathologica

Volumn 126, Issue 6, 2013, Pages 939-941

  Arita, Hideyuki ^a   Narita, Yoshitaka ^a   Takami, Hirokazu ^b,c   Fukushima, Shintaro ^b   Matsushita, Yuko ^a   Yoshida, Akihiko ^a   Miyakita, Yasuji ^a   Ohno, Makoto ^a   Shibui, Soichiro ^a   Ichimura, Koichi ^b  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE;

ARTICLE; ASTROCYTOMA; CPG ISLAND; DNA METHYLATION; ENZYME ACTIVATION; ENZYME ACTIVE SITE; GLIOBLASTOMA; GLIOMA; HUMAN; PRIORITY JOURNAL; PROMOTER REGION; TELOMERE HOMEOSTASIS; UPREGULATION; WILD TYPE;

ADULT; BRAIN NEOPLASMS; GLIOMA; HUMANS; METHYLATION; MUTATION; PROMOTER REGIONS, GENETIC; TELOMERASE; UP-REGULATION;

EID: 84892607740     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-013-1203-9     Document Type: Article

References (13)

1. Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP, Kawahara N, Shibui S, Ichimura K (2013) Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol 126:267-276
2. Castelo-Branco P, Choufani S, Mack S et al (2013) Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. Lancet Oncol 14:534-542
3. Conomos D, Pickett HA, Reddel RR (2013) Alternative lengthening of telomeres: remodeling the telomere architecture. Front Oncol 3:27
4. de Wilde J, Kooter JM, Overmeer RM, Claassen-Kramer D, Meijer CJ, Snijders PJ, Steenbergen RD (2010) hTERT promoter activity and CpG methylation in HPV-induced carcinogenesis. BMC Cancer 10:271
5. Guilleret I, Yan P, Grange F, Braunschweig R, Bosman FT, Benhattar J (2002) Hypermethylation of the human telomerase catalytic subunit (hTERT) gene correlates with telomerase activity. Int J Cancer 101:335-341
6. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D, Kumar R (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339:959-961
7. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339:957-959
8. Ichimura K, Nishikawa R, Matsutani M (2012) Molecular markers in pediatric neuro-oncology. Neuro Oncol 14 Suppl 4: iv90-99
9. Killela PJ, Reitman ZJ, Jiao Y et al (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 110:6021-6026
10. Liu XY, Gerges N, Korshunov A et al (2012) Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 124:615-625
11. Meyerson M, Counter CM, Eaton EN et al (1997) hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90:785-795
12. Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, Laurent C, Laurent A, Cherqui D, Balabaud C, Rossi JZ (2013) High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun 4:2218
13. Sturm D, Witt H, Hovestadt V et al (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22:425-437